| __timestamp | Ligand Pharmaceuticals Incorporated | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12122000 | 7459000 |
| Thursday, January 1, 2015 | 13380000 | 11831000 |
| Friday, January 1, 2016 | 21221000 | 25705000 |
| Sunday, January 1, 2017 | 26887000 | 46181000 |
| Monday, January 1, 2018 | 27863000 | 59497000 |
| Tuesday, January 1, 2019 | 55908000 | 65003000 |
| Wednesday, January 1, 2020 | 59392000 | 74506000 |
| Friday, January 1, 2021 | 69012000 | 126006000 |
| Saturday, January 1, 2022 | 36082000 | 126215000 |
| Sunday, January 1, 2023 | 24537000 | 120161000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, strategic allocation of research and development (R&D) funds is crucial for innovation and growth. Over the past decade, Protagonist Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated distinct approaches to R&D investment. From 2014 to 2023, Protagonist Therapeutics increased its R&D spending by over 1,500%, peaking in 2022 with a remarkable $126 million. This aggressive investment strategy underscores their commitment to pioneering new therapies. In contrast, Ligand Pharmaceuticals exhibited a more conservative growth, with a 200% increase in R&D expenses over the same period, reaching a high of $69 million in 2021. This steady approach reflects their focus on sustainable innovation. As the biotech landscape evolves, these companies' R&D strategies offer valuable insights into their long-term visions and market positioning.
Eli Lilly and Company or Ligand Pharmaceuticals Incorporated: Who Invests More in Innovation?
Comparing Innovation Spending: Amgen Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
Research and Development Investment: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Research and Development Expenses Breakdown: Veracyte, Inc. vs Protagonist Therapeutics, Inc.
R&D Spending Showdown: Vericel Corporation vs Ligand Pharmaceuticals Incorporated
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE
Comparing Innovation Spending: Ligand Pharmaceuticals Incorporated and Evotec SE